KaloBios Pharmaceuticals, Inc. (KBIO) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the past one month’s volatile price range of $1.70 to $2.00.
This biopharmaceutical company has seen 2 positive estimate revisions in the last 60 days. The Zacks Consensus Estimate has also moved higher over the same time frame. This implies solid trading ahead for KaloBios. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
KaloBios currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Some other Medical Drug stocks worth considering are Akorn, Inc. (AKRX), Mallinckrodt plc (MNK) and Ariad Pharmaceuticals Inc. (ARIA). While Akorn and Mallinckrodt sport a Zacks Rank #1 (Strong Buy), Ariad carries the same Zacks Rank as KaloBios.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
KALOBIOS PHARMACEUTICALS INC (KBIO): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
MALLINCKRODT PUBLIC LTD CO (MNK): Free Stock Analysis Report
ARIAD PHARMACEUTICALS INC (ARIA): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Health Care Industry